Article
Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer.
Cancer research - 15 Feb 2005
Ma Patrick C, Jagadeeswaran Ramasamy, Jagadeesh Simha, Tretiakova Maria S, Nallasura Vidya, Fox Edward A, Hansen Mark, Schaefer Erik, Naoki Katsuhiko, Lader Alan, Richards William, Sugarbaker David, Husain Aliya N, Christensen James G, Salgia Ravi
Abstract excerpt
Non-small cell lung cancer (NSCLC) is a difficult disease to treat. The c-Met receptor is an attractive potential target for novel therapeutic inhibition in human cancers. We provide strong evidence that c-Met is overexpressed, activated, and sometimes mutated in NSCLC cell lines and tumor tissues. Expression of c-Met was found in all (100%) of the NSCLC tumor tissues examined (n = 23) and most (89%) of the cell...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.